Clinical Trial

Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 22, 2022 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Soft tissue sarcoma (STS) is a kind of solid tumor with high heterogeneity. There is no standard second-line treatment plan for patients who have failed first-line treatment. NY-ESO-1, a cancer testis antigen, is highly expressed in soft tissue tumors and is an ideal therapeutic target. Investigators aim to testify the safety and efficacy of NY-ESO-1 TCR-T cell in advanced soft tissue sarcoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-11-11.
Trial Details
NCT Number NCT05620693
Lead Sponsor Shenzhen University General Hospital
Conditions Advanced Soft-tissue Sarcoma
Enrollment 20 participants
Start Date 2022-11-11
Primary Completion 2025-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2022-11-22